

ANIMAL HEALTH INVESTMENT Europe

26-27 February 2019 | 200 Aldersgate | St. Pauls, London, UK

🐦 @AHInnovation #AHInvestEurope

Programme 2019



Associate
Partners:



Headline
Partner:



Thank you to our 2019 PARTNERS

Headline Partner



Associate Partners



BioAnalytics

Consulting Partner



Knowledge Partner



Senior Event Partners



Event Partners



Media Partners



Tuesday 26th February 2019

DAY ONE



08:00 **Registration**

08:45 **Chairperson's Opening Remarks**

Jamie Brannan, Senior Vice President and Cluster Lead UK, Ireland & Nordics, [Zoetis](#)

09:00 **OPENING KEYNOTE: Fresh Perspectives on the Evolving Animal Health Landscape as Innovation in New Spaces Transforms Lives Around Us**

As the animal health industry continues to evolve and grow, top companies are investing in innovative technologies within the animal nutrition, diagnostics, therapeutics, digital and technology spaces. Combined with the adjacencies to pharma, the animal care space is now a \$60Bn*market and growing. This is a really exciting time for the industry with several factors contributing to growth and the interest in areas of emerging technology.

This presentation will examine how Zoetis, the #1 company in the industry, looks at innovation, how it will impact the lives of veterinarians and farmers and how partnerships can help seize new opportunities and accelerate growth.

Clint Lewis, EVP & Group President International Operations, Commercial Development, Global Genetics and Aquatic Health, [Zoetis](#)

09:20 **OPENING PANEL: Modern Attitudes to Meat Consumption.**

- Animal health is seen as a stable industry but is it as stable as we think?
- Consumer attitudes are changing - Can consumers feel good about eating meat?
- Animal health plays a key role in feeding the world. Will those givens stay consistent?
- How can we repair a lack of consumer confidence in meat production?

Hosted by: Clint Lewis, EVP & Group President International Operations, Commercial Development, Global Genetics and Aquatic Health, [Zoetis](#)

Joachim Hasenmaier, Head of Animal Health Business Unit, [Boehringer Ingelheim](#)

Daan Luining, CTO, [Meatable](#)

Barney Kay, Head of Agriculture, [Tesco](#)

10:00 **"Deal or No Deal - do you need to talk to the banker... or your vet?"**

Simon Doherty is the president of the British Veterinary Association. Before taking up his officer role, Simon was the Animal Science & Aquaculture Specialist for the Department for International Trade. Simon will outline how animal and public health, animal welfare, agriculture, trade and the veterinary workforce in the UK will all be affected by the UK Exit from the EU

From a shortage of vets needed to deliver increased levels of certification, to an impact on disease surveillance and licensing of veterinary medicines. The fall-out of Brexit has the potential to cut across all parts of the sector - pets, livestock, horses and aquaculture. BVA continues its campaign to raise awareness and support its members through this period of unprecedented change

Simon Doherty, President, [British Veterinary Association](#)

10:20 **Value Creation in Animal Health**

In this short presentation, McKinsey explores major drivers of value creation in an industry that has and continues to exceed market expectations, as well as catalysts for growth in the future. Growth has and will not come without change - customers are growing in size and complexity, and new entrants continue to make advances into the industry. In this rapidly evolving landscape, what should animal health players be thinking about?

Ajay Dhankhar, Senior Partner, [McKinsey & Company](#)

10:30 **Networking Break and 1-to-1 Private Business Meetings**




"[As a start-up] I think this is the best event to present at, because this is the animal health event"

- Vripi Muhonen, [Askel Healthcare](#)

Tuesday 26th February 2019

DAY ONE



11:30

ANIMAL HEALTH INVESTMENT FORUM OPENS

INVESTOR PITCHES

Six Companies to present for investment

Presenting Innovation in:

- Pet Health and Medical
- Genetics
- Vaccines, Robotics, Automation
- Data Analytics & Sensors
- Diagnostics
- Medicines

ANIMAL NUTRITION INVESTMENT FORUM OPENS

INVESTOR PITCHES

Six Companies to present for investment

Presenting Innovation in:

- Pet Nutrition and Wellness
- Immunostimulants
- Oral vaccines
- Microbiome peptides
- Insect protein
- Bacterial Phages

INVESTOR RETREAT OPENS

Investor Retreat:

An open space for start-ups, investors and strategic partners to engage in informal meetings during the main plenary sessions.

12:30

Networking Lunch – Private 1-on-1 Meeting

14:00

INVESTOR PITCHES

Six Companies to present for investment

Presenting Innovation in:

- Pet Health and Medical
- Genetics
- Vaccines, Robotics, Automation
- Data Analytics & Sensors
- Diagnostics
- Medicines

INVESTOR PITCHES

Investor pitches continue as required.

PANEL DISCUSSION: Industry Perspective on the Potential of Microbiome Innovation in Animal Health

- Is the microbiome blurring the lines between health and nutrition?
- What type of products could we expect to emerge from microbiome research?
- How is industry fueling innovation and where is it expected to come from?
- What is needed in order to translate research into commercially viable solutions?
- What can we learn from the success of microbiome applications in Human Health?
- What are the needs of industry and what challenges to overcome?
- How do we fuel microbiome innovation in Animal Health?
- To what extent could microbiome-based products replace antibiotic use?

Hosted by: **Oliver Hardcastle**, CEO, **Anizome**

Mathieu Castex, Animal Nutrition Global R&D Director, **Lallemand**

Bénédicte Flambard, Global Head, Live Therapeutics Strategic Business Unit, **Boehringer Ingelheim**

Kay O'Donnell, VP Waltham Centre for Pet Nutrition, **Mars Petcare**

Investor Retreat:

An open space for start-ups, investors and strategic partners to engage in informal meetings during the main plenary sessions.


15:00

Networking Break – Private 1-on-1 Meetings

Tuesday 26th February 2019


DAY ONE



16:00	PRESENTATION OF THE INNOVATION AWARDS: Animal Health	PRESENTATION OF THE INNOVATION AWARDS: Animal Nutrition	Investor Retreat: An open space for start-ups, investors and strategic partners to engage in informal meetings during the main plenary sessions.
16:10	Late Stage Emerging Company Presentations <p>Mazen Animal Health: Since a successful presentation at the AH Investment Europe in 2016, Mazen Animal Health accomplished all the \$1M angel round milestones – production of antigen in maize-grain platform, successful animal studies, positive meeting with regulatory authorities and affirmative feedback from future customers. Mazen is now raising a Series A equity round to further the development and manufacturing for commercialization of vaccines to be delivered with animal feed.</p> <p>Jennifer A. Filbey, CEO, Mazen Animal Health, Inc.</p> <p>ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline.</p> <p>Erwin Blomsma, CEO, ViroVet</p>	KEYNOTE: From the dairy rumen and back again: A tale of over 50,000 anaerobic rumen microbes. Discovery to Sales <p>Keynote Objectives:</p> <ol style="list-style-type: none">1. Share lessons learned from the front lines of building and selling microbiome based products to livestock producers; all the way from computational/genomics screening to animal feeding;2. The technologies and approaches necessary to dispel the antiquated microbiology dogmas that anaerobic / non-spore forming cells are not manufacturable nor deliverable;3. The role microbial genomics data sciences / practices has served in building trust and transparency with customers and their advisors in the field endomicrobial feeding solutions;4. The end of the Chemistry wave of innovation (e.g. antibiotics) is approaching the feed additive sector; how to maximize for success in the coming (Micro)Biological Wave. <p>Mike Seely, CEO, Ascus Biosciences</p>	
16:30	KEYNOTE: Computer Vision and Vets <p>Using technology, we can now turn visual information into actionable data. This technology has a wide variety of potential applications and has serious potential to impact on global sustainability issues. By providing data driven solutions we can reduce inefficiencies in food production and facilitate the more effective, environmentally sustainable use of land.</p> <p>This presentation will outline where vets come into the conversation and how vets will use this technology to detect and prevent disease in the future.</p> <p>David Hunt, Co-Founder and President, Cainthus</p>		
17:00	CLOSING KEYNOTE: A Future Vision for Animal Health and Nutrition <ul style="list-style-type: none">• The Elanco vision for evolving prevention and the control of disease in animal agriculture• Delivering on the future global demand for protein production• How the industry can address global health challenges• Innovations that will have impact and will change the industry <p>Aaron Schacht, Executive Vice President - Innovation, Regulatory & Business Development, Elanco</p>		
17:30	Chairman's Closing Remarks <p>Jamie Brannan, Senior Vice President and Cluster Lead UK, Ireland & Nordics, Zoetis</p>		
17:40 – 17:50	Welcome to the Networking Reception <p>George Gunn, Founder & CEO, Stonehaven Consulting</p>		
17:50 – 18:50	Stonehaven Consulting welcomes you to London. The team invite you to join them for drinks and canapés.		
19:00	Closure of Forum		

Wednesday 27th February 2019

DAY TWO



08:30 **Registration**

08:45 **Chairperson's Opening Remarks**

Jamie Brannan, Senior Vice President and Cluster Lead UK, Ireland & Nordics, [Zoetis](#)

08:55 **Special Welcome**

Professor the Lord Trees

09:00 **PANEL DISCUSSION: Preventative Care: What's Next in Companion Animal Diagnostics**

Humanization of pets and pre-human release of the most advanced technologies into veterinary and animal science diagnostics have become key drivers for the growth of the diagnostics market. These and other factors have triggered parabolic demand for more innovative animal health diagnostics & data services, which are expected to drive the market growth.

- The challenges facing a market leading diagnostics company
- Advice for animal diagnostics start-ups
- Market drivers and where innovation can make an impact
- Educating veterinarians on the value of diagnostics

Hosted by: **Jean-Louis Hunault**, Secretary Général, [Diagnostics For Animals](#)

Berwyn Clarke, CEO, [PBD Biotech](#)

Kathy Turner, Corporate Vice President, EMEA & Asia Pacific, [IDEXX Europe B.V.](#)

Bruno Cluzel, Senior Director, Diagnostics, [Zoetis](#)

09:30 **PANEL DISCUSSION: The Future of Companion Animal Parasiticides**

The discovery, development and marketing of animal health anti-infective products are at an important crossroads. Traditional anti-infective products include antibiotics, parasiticides and vaccines, which are administered to either food production or companion animals. The convergence of market conditions, new regulatory guidance, political decisions and food safety concerns has led to a redirection of research away from traditional antibiotics and towards other products that have an increased probability of acceptance in the marketplace and shareholder return. This session will examine the current state of development in parasiticides products, consumer attitudes and future innovation.

Hosted by: **Sébastien Lafon**, Founder, [Adapt1st LLC](#)

Aaron Schacht, Executive Vice President - Innovation, Regulatory & Business Development, [Elanco](#)

Douglas Hutchens, SVP, Head of Drug Discovery, External Innovation and Chief Veterinary Officer, [Bayer Animal Health](#)

Sébastien Huron, Chairman of the Executive Board, [Virbac Santé Animale](#)

10:00 **PANEL DISCUSSION: Gender Diversity in Animal Health**

- The majority of customers in the vet profession are women, how does that impact purchasing decisions?
- How does gender diversity work to improve connections with customers?
- The business case for more women in senior positions that involve decision making.

Host: **Linda Rhodes**, VMD, PhD, [Independent](#)


Marie-Paul Lachaud, DVM, Head of Program Management Europe, [Aratana Therapeutics](#)

Charlotte Bunyan, Head of Strategy, [Collider](#)

Julie Lawless, Vice President, Corporate Affairs and Administration, Office of the CEO, [Elanco](#)

10:30 **Networking Break – Private 1-on-1 Meetings**





VETERINARY PRACTICE TRACK

ANIMAL HEALTH TRACK

HUMAN HEALTH TRACK

11:30

PANEL DISCUSSION: The Changing Face of the Veterinary Profession

- Internationalization. With the UK now at 70% market share, what's next in terms of growth for corporate vet practice?
- What does consolidation mean for the big pharma companies? If corporates do sell their own brand medicines, how will pharma companies interact and engage corporates in the future?
- Compliance - how do you drive growth and improve product compliance in the UK when the consolidation play is coming to an end?
- What role will technology such as telemedicine and wearable technologies play in compliance and identifying health issues.

Hosted by: **Matt Dobbs**, CEO, **Westpoint**

Simon Innes, CEO, **CVS Group**

Clint Lewis, EVP & Group President International Operations, Commercial Development, Global Genetics and Aquatic Health, **Zoetis**

Brian Topper, Managing Director, **AmerisourceBergen Animal Health UK**

DIGITAL PERSONALIZATION IN PET CARE: How Pet Wearables Will Influence the Health and Wellbeing of Companion Animals

Pet owners can now track their pet's physical activity, location, and health metrics with pet wearables, Fitbit-style monitoring devices. Internet-connected video cameras and treat dispensers have been upgraded to allow pet owners to engage with their pets via Skype-like connections and dispense food while away from home. The goal of these smart devices is to eliminate stress for busy pet owners and to better care for the needs of dogs and cats.

How can these solutions influence consumer engagement and how can companies leverage the data provided by these products to improve consumer adoption and product compliance?

Hosted by: **Joseph Harvey**, Editor, **Animal Pharm**

Davide Rossi, CEO, **Fitbark**

James Andrews, CEO and Founder, **Felcana**

Nick Hill, Head of Pet Care, **Antelliq**

PANEL DISCUSSION: Why Humans are Really the Guinea Pigs for Animal Health Drug Discovery and Innovation

- How important is having a product derived from human biotech a factor from a veterinarian's perspective for prescribing a new medicine/class? Real world validation where translational medicine has worked - taking a human medicine or technology and successfully providing its value in AH
- How the field has changed from the perspective of human health companies in using veterinary medicine for drug discovery. Covering notable examples and the pros and cons
- The advantages and challenges in taking a product from human medicine into AH. The misconceptions and why AH is something human companies should consider.
- The top 3 things you should know as a human company taking your technology into animal health

Hosted by: **Mark Heffernan**, CEO, **Stonehaven Incubate**

Duncan Lascelles, Professor of Surgery and Pain Management, **North Carolina State University**

Jolyon Martin, Founder and Head of Business Development, **PetMedix**

Joe Petrosino, Director of the Center for Metagenomics and Microbiome Research and Interim Chairman of the Department of Molecular Virology and Microbiology, **Baylor College of Medicine**

12:30 **Networking Lunch – Private 1-on-1 Meetings**




“There are an amazing number of commonalities [between human and animal health]. The big ones: chronic kidney disease, chronic heart disease, different types of cancers, diabetes; are all big areas that have significant unmet needs in veterinary medicine that have a lot of technology on the human side that could be applicable”

- **Linda Rhodes**, **VMD Ph.D**

Wednesday 27th February 2019

DAY TWO



14:00

FIRESIDE CHAT: How do Independent Veterinarians Remain Independent

- How do modern independent veterinarians respond to the rise of corporatisation?
- What are needs and drivers of a modern vet vs the 'baby boomer' generation?
- How will technology play a role in the future of vet practice?

Hosted by: **Robin Hargreaves**, Director, **Stanley House Veterinary Group LTD**

Peter McCarthy, Senior Adviser to **Henry Schein, Inc.**

PANEL DISCUSSION: Venture Capital Perspective on the Animal Health Market:

- How animal health start-up funding options are different to funding options in other industries
- Raising capital in animal health is difficult, what can VC's do to improve the situation?
- How does a typical VC make an assessment of an earlystage company?

Hosted by: **Maarten Goossens**, Co-founder and Principal, **Anterra Capital**

Laëtitia Gerbe, Partner for investments for AVF fund, **Seventure**

Joost Matthijssen, Investment Director, **Nutreco NuFrontiers**

Rob Readnour, Managing Director, **Mountain Group Partners**

Showcase of Human Health Biotech:

Four human health companies to present their innovations for possible applications in animal health.

14:30

DISCUSSION: How to Innovate the Veterinary Industry:

- How to grow your vet practice in the next 3-5 years using technology
- Needs and drivers of the modern veterinarian. Baby boomers vs millennials.
- Opportunities for innovation in the vet industry. US vs EU

Hosted by: **Lawrence Brown**, Specialist for Animal Sciences & Aquaculture, **Department for International Trade**

Cindy Barnes, CEO, **Shepherd Software Inc**

David Perin, CEO, **First Vet**

Emma Harris, CEO, **Healthypets**

SUCCESSFUL M&A IN ANIMAL HEALTH: What does it take?

- What are the current trends and dynamics of the investment and M&A landscape in animal health?
- What are the 'hot' areas for investment right and where will we continue to see growth?
- Are animal health and animal nutrition good areas for investment?

Hosted by: **Ajay Dhankhar**, Senior Partner at **McKinsey & Company**

Justine Conway, Director, **Bank of America Merrill Lynch**

Spencer Swayze, Managing Director, **Paine Schwartz Partners, LLC**


Christian Fellowes, Vice President, **GHO Capital Partners LLP**

15:00

Networking Break – Private 1-on-1 Meetings

Wednesday 27th February 2019

DAY TWO



16:00 Professionalizing the Pet Health Business.

- What are the corporates' strategies for changing Pet Health?
- 50% of people don't go to the vet. How do we increase consumer engagement?
- What role will integrated health solutions play?

Hosted by: **Simon Doherty**, President, **BVA**

Rachel Dean, Director of Clinical Research and Excellence in Practice, **VetPartners Ltd**

Roy Stein, CEO, **Babelbark**

Anthony Roberts, Director of Leadership and Innovation, **Royal College of Veterinary Surgeons (RCVS)**

Insect Protein

- Commercial & regulatory bottlenecks
- Social acceptance
- Demonstrating the insect protein product as a speciality ingredient with a high value vs being viewed as a commodity
- Opportunities for insect protein across the value chain
- Human health applications

Hosted by: **James Millar**, CCO, **Entocycle**

Antoine Hubert, CEO, **Ynsect**

Joost Matthijssen, Investment Director, **Nutreco NuFrontiers**

Patrick Charlton, CEO, **Alltech Coppins**

Showcase of Human Health Biotech:

Four human health companies to present their innovations for possible applications in animal health.

16:40 Close of Main Conference

16:45 - 18:00 Networking Break – Private 1-on-1 Meetings



"It's mind-blowing really, that a molecule that we could discover computationally for one disease could be flipped and used to impact animals"

- Sean Ekins, CEO, **Collaborations Pharma**



ANIMAL HEALTH INVESTMENT USA

10-11 April 2019

Boston, USA


www.animalhealthinvestusa.com

10% OFF
your pass to all
upcoming Animal
Health events
with code
LONDON10

Meet the financial investors that
will change the animal health industry.

Our investor conference in Boston brings together domain experts and institutional investors to present the current trends and dynamics of the animal health industry and to outline where capital investment can make an impact.

INVESTOR PASSES STILL AVAILABLE - speak to a
member of the team for more information



HUMAN BIOTECH & ANIMAL HEALTH BUSINESS PARTNERING SUMMIT

9 April, 2019

Boston, USA

www.humanbiotechanimalhealth.com

Join the first ever
conference series connecting human
biotechs with the animal health industry.

We'll be connecting innovative biotechnology from human medicine with veterinary expertise to accelerate R&D in animal health, and to promote a global and holistic approach to healthcare

- Find out how you could benefit from a collaboration!

INNOVATION SHOWCASE FINALISTS – HEALTH



Claudia Jimenez
General Manager
Algenex (Alternative Gene Expression)



About Algenex: Alternative Gene Expression S.L. (ALGENEX) has developed CrisBio® technology, which consist in natural bio-reactors which have unique advantages for industrial production of any kind of recombinant protein, offering the most simple, cost-effective and scalable production technology up to date. CrisBio® has multiple advantages to obtain biotechnological high-tech products, with respect to classical production based on bioreactors.

Website: www.algenex.com



Jelena Šuran
Head of Department of
Pharmacology and Toxicology
ApiotiX Technologies



About ApiotiX Technologies: At APIOTIX TECHNOLOGIES we are dedicated to developing antibiotic phytochemical alternatives that are effective, sustainable and cost-effective. Our flagship product ApiMast is a first organic antibiotic alternative for treatment of mastitis in dairy cows that is to be registered as a veterinary medicinal product (VMP). ApiMast is an intramammary solution based on our proprietary, unique extraction and standardization technology.

Website: www.apipet.eu



Sofiane Bennacer
Business Development Manager
Credo Biomedical



About Credo Biomedical: Our aim is to empower veterinarians with powerful diagnostic tools and help them make the right diagnosis directly at the clinic. By providing Nucleic Acid Tests at similar price level to rapid tests and with the accuracy of laboratory testing, we aim to enable veterinarians to make critical decisions faster and with more confidence.

Website: www.credobiomed.com



Dr. Sam Dylan Moré
CEO
DendroPharm



About DendroPharm: We have developed an analgesic drug nanotech platform technology that solves the US opiate crisis and which offers a not controlled non-addictive medication for strong to moderate pain.

Website: www.dendropharm.de



Dr. Bevyn Jarrott
FelCan Pharma



About FelCan Pharma: In the Western world, owners of companion pets (mainly cats and dogs) are willing to pay high prices for drugs that clearly relieve the pain and suffering from degenerative disorders that are a feature both of ageing and also inbreeding of strains. The major disorders are joint arthritis, heart and kidney failure and epilepsy. Ideal drugs are those that can be given in food pellets once a day and improve the health and behaviour of the pets thus justifying the costs to the owners.

Website: www.felcanpharma.com (under construction)




Professor Dr. Martin F. Bachmann
CSO and Co-founder
HypoPet AG



About HypoPet AG: HypoPet is a Swiss biotech company engaged in the research, development, manufacture and licensing of therapeutic vaccines for major unmet needs in companion animal medicine; allergy, inflammation, pain, cardiovascular and metabolic disease and cancer.

Website: www.hypopet.ch



INNOVATION SHOWCASE FINALISTS - HEALTH



Bruno Oesch
CEO
Malcisbo AG



About Malcisbo AG: Malcisbo's unique biotechnology platform is based on glycoengineering technologies, generating effective glyco-conjugate vaccines for unmet medical needs. Our first platform-derived product is a chicken vaccine against *Campylobacter* to reduce bacteria in chicken gut and thereby reducing exposure of humans and as a consequence prevent food poisoning. Our patent-protected vaccine offers comprehensive protection against all *Campylobacter* species and serotypes, a major market requirement.

Website: www.malcisbo.com



Polyana Tizioto
Director
NGS Soluções Genômicas



About NGS Soluções Genômicas: NGS Genomic Solutions is a technology-based company dedicated to research and development in the area of genomics applied to animal health and production. The company uses next-generation sequencing (NGS) applications for microbiome identification and diagnosis as well as antibiotic susceptibility to support effective treatment and management strategies for disease control and increased production.

Website: www.ngsgeonomica.com.br



Amado Guloy
CEO
Rex Animal Health



About Rex Animal Health: At Rex, we help livestock producers optimize yields and manage disease in their herd using machine learning. Our software solutions are a simple, intuitive platform for: Disease Tracking; Disease Forecasting; Clinical Decision Support; Antimicrobial Resistance Surveillance; Drug Efficacy & Outcomes; Breeding & Performance Support.

Website: www.rexanimalhealth.com



Pravin Kini
CEO and Co-Founder
Tropical Animal Genetics



About Tropical Animal Genetics: We aim to advance animal-sciences using genetics, gene-editing and automation to create a sustainable and food-secure future for humanity. Our disruptive species-agnostic In Vitro Breeding Platform (IVBP) aims to deliver increased yields and resilience across livestock species. IVBP eliminates the need for traditional selective breeding methods by rapidly fixing desired traits in foodproducing animals. IVBP is the future of affordable & sustainable animal protein production.

Website: www.taggnx.com



Dr. Apryle A. Horbal, VMD, MRCVS
President & Founder
VetNOW



About VetNOW: Veterinary and Animal health organizations have been slow to take advantage of the standardization than other industries that have capitalized on driving common processes, reducing unintended variability, and ensuring consistency in experience by developing care pathways. VetNOW takes a comprehensive approach to the limited version of Tele Health currently practiced and produces a more resilient Vet to Client experience while promoting cultural change and sustainability.

Website: www.vetnow.com




Francisco Manuel Reyes Sosa
Business Development Manager
VLPbio



About VLPbio: VLPbio is a technological company that develops novel vaccines against high-impact diseases in the veterinary sector using proprietary technology based on chimeric virus-like particles that act as an antigens-display platform specifically designed for each pathology which generates an immune response.

Website: www.vlpbio.com



NOVATION SHOWCASE FINALISTS - NORTH AMERICAN REGION

Mary Keenan
International Business Development
EKOGEA



EA: Our unique prebiotic tool (BCx) directly and supports the microbiome. Specialised mechanisms feed microbial populations, creating robust proliferation diversity to meet the challenges of AMR, young nutrient optimisation, and production profitability. Our prebiotic offers the co-benefit of lowering the impact of animal feeding operations to provide a sustainable solution within the animal health sector.

www.ekogea-int.com



Georgios Savoglidis
CEO
Embion Technologies



About Embion Technologies: Embion - producing affordable prebiotics for greater animal health and performance using sustainable food side-stream feedstocks. Embion has developed a unique, patented form of catalysis, proven at 5 litre reactor scale in the laboratory, and about to commercialise at pilot facility scale.

Website: www.embiontech.com

Edward Fuchs
Chief Executive and Co-Founder
FOLIUM Science



FOLIUM Science: One of the biggest stories of modern agriculture is the overuse of antibiotics and the development of antibiotic resistance. FOLIUM Science is developing a new technology that will help solve part of the issue. With game-changing science that harnesses naturally occurring mechanisms to remove unwanted pathogenic and spoilage bacteria, FOLIUM Science is working to deliver solutions for increased productivity at all points in the food and agriculture value chain.

www.foliumscience.com



Tangai Marega
Founder
Northyde Life Sciences



About Northyde Life Sciences: Northyde Life Sciences aim to pioneer IoT driven precision animal husbandry for the approximately 21-30 million small ruminant livestock through application of neural sensor networks. This translates to an annual average of US\$1.5 billion unmet need. AI based machine learning and control systems for early disease or distress detection instrumental to the company's long-term success. We are a pioneer R&D enterprise to introduce a scalable high class end to end optimal sustainable solution to our clientele.



INNOVATION SHOWCASE FINALISTS – NUTRITION



Hannah Braun
Co-Founder, COO
PerformaNat GmbH



About PerformaNat GmbH: PerformaNat is a Berlin based biotech startup company that develops new animal nutrition additives to increase and maintain animal health. We identify and characterize new compounds using our own technology. We develop patented products from this that can be used to prevent metabolic disorders and support the immune system, including products that support the animal in critical phases, such as after calving or during weaning.

Website: www.performanat.de



Matthew Tebeau
Chief Operating Officer
Proteon Pharmaceuticals



About Proteon Pharmaceuticals: Proteon's bacteriophage-based products are an effective alternative to the use of antibiotics in livestock farming and aquaculture. Our products prevent and eliminate targeted bacterial disease, improving food safety, increasing economic efficiency and enhancing environmental sustainability. They have no side effects, leave no residue and are safe to use on animals and humans. Importantly, Proteon's products significantly reduce the risk of anti-microbial resistance.

Website: www.proteonpharma.com



Geraf Zimmermann
Business Development
purapep




About purapep: purapep helps dogs and cats to live a long and vital life by using natural whey protein hydrolysates. The products contain special bioactive peptides which support the maintenance of a healthy cardiovascular system in cats and dogs. Our supplements are part of the daily balanced nutrition which supplies the pet in addition to bioactive peptides with essential amino acids. purapep products serve as a natural prevention and therefore closes the gap between nutrition and medication and support a long and vital life for cats and dogs.

Website: <https://purapep.de/>



"It's mind-blowing really, that a molecule that we could discover computationally for one disease could be flipped and used to impact animals"

- Sean Ekins, CEO, Collaborations Pharma



INNOVATION SHOWCASE FINALISTS - TRANSLATIONAL FROM HUMAN PHARMA



Deborah Dullen
President & CEO
BioTrace IT



About BioTrace IT: Instantaneous, Real-time, Acute and Chronic Pain Measurement.

BioTraceIT™'s patented technology has been independently proven to effectively quantify pain in canine, equine, feline, and human patients. Skin-mounted sensors process a direct pain biosignal generated by the nervous system. From prep to clean up in five minutes.

Research has demonstrated the capacity of PainTrace® to differentiate between acute and dull pain, and to measure the duration and magnitude of pain.

Website: www.biotraceit.com



Anja E. H. Holm
CEO
Panion Animal Health AB



About Panion Animal Health AB: Panion Animal Health's aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy based on CombiGene AB's technology and platform. In addition, Panion aims at inlicensing or acquiring other, similar assets, i.e. animal health applications of human health development projects or products.

Website: panion-animalhealth.com



Dr. Thomas Weaver
CEO
PetMedix



About PetMedix: PetMedix is a Cambridge, UK based early stage pharmaceutical company with global ambitions to become the world leader in innovative antibody-based therapeutics for the companion animal market. We will deliver the first transgenic mouse platform capable of producing therapeutic-quality antibody drugs fully adopted to the target companion animal.

Website: www.petmedix.co.uk




Carl Damiani
President
Simini Technologies



About Simini Technologies: Simini Technologies' mission is to mine the human health universe for animal health products. The Company is developing a novel topical cyclosporine product that has demonstrated rapid onset efficacy in a Phase 2 study of human atopic dermatitis together with a low systemic cyclosporine exposure to create a unique drug candidate in canine atopic dermatitis. Simini's commercial anti-infective products are aligned with initiatives to reduce antibiotic use in animal health.

Website: www.simini.com



Animal Health Innovation Europe is part of the ANIMAL HEALTH GLOBAL SERIES:



**ANIMAL HEALTH
INVESTMENT USA**

10-11 April 2019
Boston, USA



**ANIMAL HEALTH
INNOVATION**
Latin America

6-7 August 2019
Sao Paulo, Brasil



**AQUACULTURE
INNOVATION Europe**

10-11 September 2019
London, UK



**ANIMAL HEALTH
INNOVATION ASIA**

6-7 November 2019
Tokyo, Japan



**ANIMAL HEALTH
INVESTMENT Europe**

26-27 February 2020
London, UK



4

Annual
Events



800+

Delegates
Last Year



50+

Selected
Innovations



90+

Industry
Speakers



1700+

Meetings
Booked in 2018

COMPLIMENTARY EVENTS:



**ANIMAL
MICROBIOME
CONGRESS USA**

13-14 March 2019
Kansas City, USA



**HUMAN BIOTECH &
ANIMAL HEALTH
BUSINESS PARTNERING SUMMIT**

9 April 2019
Boston, USA



**ANIMAL
MICROBIOME
CONGRESS**

9-10 July 2019
London, UK

PETS & MONEY

10-11 December 2019
USA

PETS & MONEY

28 February 2020
London, UK

Join the community: @AHInnovation #AHInvestEurope